Salmonella typhi Infection |
|
|
Clinical Trial: Safety and Efficacy of the Therapeutic Vaccine GI-5005 Versus Placebo for the Treatment of Chronic Hepatitis C Infection.
This study is currently recruiting patients.
Verified by GlobeImmune July 2005
|
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| Hepatitis C Infection | Vaccine: GI-5005 | Phase I |
MedlinePlus consumer health information
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study
Official Title: A Phase 1 Double-Blind, Placebo Controlled, Dose-Escalation, Multi-Center Therapeutic Trial of the Safety, Immunogenicity, and Efficacy of GI-5005; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing a Hepatitis C Virus NS3-Core Fusion Protein, in Patients with Chronic Hepatitis C Infection.
Expected Total Enrollment: 48
Study start: June 2005
Eligibility
Inclusion Criteria: Patients with chronic hepatitis C virus infection including treatment naive subjects as well as subjects who are partial responders and relapsers to prior interferon therapy, >18 years of age, negative skin test for hypersensitivity to saccharomyces cerevisiae.
Exclusion Criteria: non-responders to previous interferon treatments, cirrhosis, HCV treatment within 3 months, hepatitis B infection, HIV infection.
Location and Contact Information
California
Huntington Medical Research Institutes, Pasadena, California, 91105, United States; Recruiting
Myron Tong, M.D., Principal Investigator
Colorado
University of Colorado Health Sciences Center, Denver, Colorado, 80262, United States; Recruiting
Gregory Everson, M.D., Principal Investigator
Florida
University of Miami, Miami, Florida, 33136, United States; Recruiting
Eugene Schiff, M.D., Principal Investigator
Illinois
University of Chicago, Chicago, Illinois, 60637, United States; Recruiting
Helen Te, M.D., Principal Investigator
Donald Jensen, M.D., Sub-Investigator
New York
Weill Medical College of Cornell University, New York City, New York, 10021, United States; Recruiting
Ira Jacobson, M.D., Principal Investigator
More Information
Last Updated: August 1, 2005
Record first received: July 26, 2005
ClinicalTrials.gov Identifier: NCT00124215
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-08-02

Not Signed In -


